Haemodynamic effects of ketanserin following coronary artery bypass grafting

• Published in: Anaesthesia and intensive care 1991-08, Vol.19 (3), p.351-356
• Main Authors: LEE, E. J. E, LEE, T. L, WOO, M, BOEY, W. K, KUMAR, A, LEE, C. N
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antihypertensive agents; Biological and medical sciences; Blood Pressure - drug effects; Cardiovascular system; Coronary Artery Bypass - adverse effects; Heart Rate - drug effects; Hemodynamics - drug effects; Humans; Hypertension - prevention & control; Infusions, Intravenous; Injections, Intravenous; Intensive Care Units; Ketanserin - administration & dosage; Ketanserin - therapeutic use; Medical sciences; Middle Aged; Nitroprusside - administration & dosage; Nitroprusside - therapeutic use; Pharmacology. Drug treatments; Pulmonary Artery; Time Factors
• ISSN: 0310-057X; 1448-0271
• DOI: 10.1177/0310057x9101900307

The haemodynamic effects of ketanserin were studied consecutively in seventeen patients in the intensive care unit following coronary artery bypass grafting. Hypertensive patients (Group 1, systolic blood pressure (SBP) greater than or equal to 150 mmHg following discontinuation of nitroprusside, n = 10) received intravenous ketanserin 10 mg and infusion of 0.1 mg.kg-1.hr-1 with additional boluses as required to maintain SBP less than or equal to 130 mmHg for one hour. Non-hypertensive patients (Group 2, SBP less than 150 mmHg, n = 7) received a 5 mg bolus and the same infusion. Ketanserin significantly decreased arterial blood pressure (P less than 0.001) in all patients in Group 1. Heart rate was decreased but not significantly. Cardiac index, systemic and pulmonary vascular resistance and pulmonary shunt fraction were not significantly altered from pre-ketanserin values when blood pressure was controlled with nitroprusside. Normotensive patients in Group 2 did not show any undesirable hypotension or significant haemodynamic changes. Mean nitroprusside dose requirements following ketanserin therapy were significantly reduced by 91.6% in Group 1 and 78.4% in Group 2 (P less than 0.05). Ketanserin is effective in treating hypertension following coronary artery bypass grafting with an advantage of lack of reflex tachycardia.